Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430306 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
A Phase 3 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
NCT07430306 is a Phase 3 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 245 participants.
The verdict
NCT07430306, a Phase 3 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.
Interventions
- DRUG Anifrolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2029-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07430306
The ClinicalTrials.gov registry entry for NCT07430306 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anifrolumab is the first listed.
NCT07430306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07430306 about?
NCT07430306 is a clinical study titled "A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus". The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any...
What is the current status of trial NCT07430306?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2026-04-13. Estimated completion is 2029-01-26.
What interventions are being tested in trial NCT07430306?
The interventions under investigation include: Anifrolumab (DRUG).
Who is sponsoring clinical trial NCT07430306?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.